Key result
Nebivolol/valsartan and amlodipine/valsartan showed no significant difference in reducing day systolic blood pressure at 12 weeks in patients with hypertension.
Why the study?
Because nebivolol exerts moderate beta-blockade and reduces peripheral arterial resistance, its antihypertensive effect combined with valsartan was evaluated against amlodipine/valsartan on 24-hour ambulatory blood pressure in patients with grade II or III hypertension or uncontrolled blood pressure.
Does nebivolol/valsartan reduce 24-hour ambulatory blood pressure compared to amlodipine/valsartan in patients with grade II/III or uncontrolled hypertension?
RCT (n=74)
Randomized
Does nebivolol/valsartan reduce 24-hour ambulatory blood pressure compared to amlodipine/valsartan in patients with grade II/III or uncontrolled hypertension?
Answers are grounded in this paper and cite their sources.
Both nebivolol/valsartan and amlodipine/valsartan combinations are equally effective in reducing 24-hour ambulatory blood pressure in patients with grade II/III or uncontrolled hypertension.
BACKGROUND: Nebivolol has a dual mechanism of action, exerting a moderate b- blockade effect and reducing peripheral arterial resistance, as a result, the antihypertensive effect of nebivolol may be higher than that of a potent vasodilator CCB such as amlodipine. AIM: The study evaluated the effect of two nebivolol/valsartan on 24 hour ambulatory blood pressure versus amlodipine/valsartan in grade II or III hypertension patients or having uncontrolled BP despite treatment. Ambulatory blood pressure monitoring is a powerful method to monitor the changes in blood pressure over the 24 hour. MATERIALS AND METHODS: A total of 74 from 90 patients continued the study. Fourty patients received amlodipine 10 mg/valsartan 160 mg (group I), and thirty-four patients received nebivolol 5 mg/ valsartan 160 mg (group II). Peripheral blood pressure readings were measured at randomization at 6 and 12 weeks. Ambulatory blood pressure was measured at randomization and 12 weeks. RESULTS: Both drug combinations showed high efficacy in reducing peripheral and 24 hour ambulatory BP. There was no statistically significant difference between the groups in lowering peripheral systolic and diastolic blood pressure at 6 and 12 weeks. Furthermore, both groups failed to show any significant difference in reducing 24 hour SBP and DBP. Regarding day SBP, the blood pressure dropped by -5.63 ± 14.87 in group I and -6.25 ± 11.59 in group II (p = 0.844). Also, group I reduced the day DBP average by -2.53 ± 9.83 and group II by -3.61 ± 9.78 (p = 0.640). In addition, both drug combinations had no statistically significant difference in lowering night SBP and DBP average. CONCLUSION: Both treatment groups reached the target ambulatory blood pressure, and there was no statistically significant difference between both groups as a regard reduction in all ambulatory blood pressure readings.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2023) conducted an RCT in Hypertension (n=74). Nebivolol/valsartan vs. Amlodipine/valsartan (10 mg / 160 mg) was evaluated on Reduction in day systolic blood pressure (p=0.844). Nebivolol/valsartan and amlodipine/valsartan showed no significant difference in reducing day systolic blood pressure at 12 weeks in patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: